B. Metzler seel. Sohn & Co. AG Decreases Stock Position in AbbVie Inc. $ABBV

Key Points

• B. Metzler seel. Sohn & Co. AG cut its AbbVie stake by 8.7% in the second quarter, selling 82,764 shares and retaining 867,621 shares valued at approximately $218.3 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted earnings of $3.65 per share, exceeding analyst estimates; revenue increased 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• AbbVie pays a quarterly dividend of $1.73, equivalent to a $6.92 annualized payout and a 2.8% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $275.95.

B. Metzler seel. Sohn & Co. AG lessened its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 8.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 867,621 shares of the company's stock after selling 82,764 shares during the period. AbbVie comprises about 1.9% of B. Metzler seel. Sohn & Co. AG's holdings, making the stock its 14th largest holding. B. Metzler seel. Sohn & Co. AG's holdings in AbbVie were worth $218,327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ABBV. ACT Advisors LLC. boosted its stake in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after purchasing an additional 41 shares during the period. Willner & Heller LLC increased its position in shares of AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC raised its stake in shares of AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after acquiring an additional 43 shares during the last quarter. Fielder Capital Group LLC boosted its holdings in shares of AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock worth $637,000 after purchasing an additional 43 shares during the period. Finally, Leslie Global Wealth LLC grew its stake in shares of AbbVie by 1.5% in the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock worth $751,000 after purchasing an additional 44 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $251.04 on Thursday. The stock has a market cap of $443.53 billion, a price-to-earnings ratio of 70.92, a PEG ratio of 1.13 and a beta of 0.29. The firm's 50-day moving average is $254.66 and its 200 day moving average is $230.55. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm posted $2.97 EPS. AbbVie's revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie's dividend payout ratio is 195.48%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research analyst reports. Royal Bank Of Canada increased their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, July 10th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research note on Tuesday, June 23rd. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. UBS Group boosted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. Finally, Morgan Stanley restated an "overweight" rating and issued a $296.00 price objective on shares of AbbVie in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and a consensus target price of $275.95.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.